To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).

开始日期2026-02-01

申办/合作机构

University of Texas Health Science Center At San Antonio

[+1]

NCT07044700

/ Not yet recruitingN/A

Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China

This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
The primary objective is to compare the risk of the composite outcome of cardiovascular (CV) death or hospitalisation for heart failure (HHF) in heart failure with reduced ejection fraction (HFrEF) patients initiating Jardiance with propensity score (PS) matched HFrEF patients initiating guideline-recommended non-sodium-glucose cotransporter-2 inhibitors (SGLT2i) medications (angiotensin-converting-enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), betablockers, and mineralocorticoid receptor antagonist (MRA)) in China, measured by the hazard ratio of the two groups.

开始日期2026-01-31

申办/合作机构

Boehringer Ingelheim GmbH

NCT06625073

/ Not yet recruiting临床4期IIT

Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients

Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease. Large randomized clinical trials have recently shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) have potent kidney protective and CV benefits in many populations of patients with chronic kidney disease (CKD), CV disease and/or diabetes. SGLT2i have not been studied prospectively in HTx recipients, which represents a barrier to their use in this population.
In this multicenter randomized controlled trial in Veterans with HTx, investigators will evaluate the potential benefits of empagliflozin on kidney function, cardiometabolic risk, erythropoiesis, and functional status. A total of 200 Veterans will be randomly assigned to receive either empagliflozin 10 mg daily or a matching placebo for 12 months.

开始日期2026-01-02

申办/合作机构

VA Office of Research and Development

100 项与恩格列净相关的临床结果

登录后查看更多信息

100 项与恩格列净相关的转化医学

登录后查看更多信息

100 项与恩格列净相关的专利（医药）

登录后查看更多信息

4,313

项与恩格列净相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-utility analysis of empagliflozin for heart failure in the Philippines

Article

作者: Llanes, Elmer Jasper ; Salvador, Dante ; Añonuevo, John ; Montilla, Precious Juzenda ; Ong-Garcia, Helen ; Encarnacion, Patrick James ; Taneo, Mary Joy ; Aquino, Camilo Oliver ; Orolfo, Diana Dalisay ; Villanueva, Anthony Russell ; Permejo, Chito ; Cunanan, Elaine

AIMS:

Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.

METHODS:

Using a Markov model, we predicted lifetime costs and clinical outcomes associated with treating HF in the Philippine setting. We used estimates of treatment efficacy, event probabilities, and derivations of utilities from the EMPEROR trials. Costs were derived from hospital tariffs and expert consensus. Separate analyses were performed for patients with left ventricular EF > 40%, categorized under mid-range ejection fraction or preserved ejection fraction (HFmrEF/HFpEF), and patients with left EF ≤ 40%, categorized under HF with reduced ejection fraction (HFrEF).

RESULTS:

Our model predicted an average of 0.09 quality-adjusted life year (QALY) gains among HFmrEF/HFpEF patients and HFrEF patients when empagliflozin was compared to SoC. The addition of empagliflozin in the treatment results in a discounted incremental lifetime cost of PHP 62,692 (USD 1,129.99) and PHP 17,215 (USD 308.67) for HFmrEF/HFpEF and HFrEF, respectively. The incremental cost-effectiveness ratio (ICER) of empagliflozin is PHP 198,270 (USD 3,570.72)/QALY and PHP 742,604 (USD 13,385.08)/QALY for HFrEF and HFmrEF/HFpEF, respectively.

LIMITATIONS:

This study employed parameters derived from short-term clinical trial data, alongside metrics representative of Asian populations, which are not specific to the Philippine cohort.

CONCLUSIONS:

Adding empagliflozin to the SoC in comparison to the SoC is associated with improved clinical outcomes and quality-of-life, at additional costs for both HFrEF and HFmrEF/HFpEF.

2025-12-01·Current Neurology and Neuroscience Reports

The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

Review

作者: Moustafa, Bayan ; Trifan, Gabriela

PURPOSE OF REVIEW:

Diabetes is a well-established risk factor for stroke. Understanding the pathophysiology of this connection is crucial to implementing appropriate prevention strategies. Lately, there has been a paradigm shift in the care of individuals with diabetes toward the use of glucose-lowering medications with potential cardiovascular, cerebrovascular or cardiorenal benefits. The aim of this article is to provide a critical analysis of the role of diabetes in cerebrovascular disease and current evidence and recommendations for the use of glucose-lowering medication with particular focus on the sodium glucose cotransporter-2 inhibitor (SGLT2i) class.

RECENT FINDINGS:

Intensive glycemic control in individuals with diabetes reduces the risk of microvascular complications, but there is less clear evidence for decreasing risk of macrovascular events (e.g., stroke). A multifaceted management of diabetes addressing healthy lifestyle practices, glycemic control, and optimization of other cardiovascular risk factors is highly recommended. SGLT2i are the latest class of antihyperglycemic agents available for diabetes management. Canagliflozin and empagliflozin are associated with reduction in major adverse cardiovascular events (MACE). Dapagliflozin did not reduce the rate of MACE but is associated with reduction in heart-failure related death and hospitalization and has the potential to decrease dementia risk. Ertugliflozin decreases rates of hospitalization related to heart failure however it was non-inferior to placebo in reducing MACE. There is increasing evidence that the use of SGLT2i may reduce the risk of stroke, particularly hemorrhagic stroke, in individuals with type 2 diabetes and a high risk of cardiovascular events, and that SGLT2i may also be beneficial for brain health by decreasing risk of cognitive decline and dementia. Antihyperglycemic therapy should be tailored to patients' circumstances. SGLT2i treatment should be considered in patients with type 2 diabetes and established or high-risk cardiovascular disease, heart failure, or chronic kidney disease, to reduce the overall cerebro-cardiovascular and renal risks.

2025-12-01·ANNALS OF MEDICINE

Efficacy and safety of empagliflozin for the acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Review

作者: Peng, Lei ; He, Youfu ; Yin, Jing ; Fan, Jun ; Zhang, Zhongnan

OBJECTIVE:

This study aims to evaluate the efficacy and safety of empagliflozin in acute myocardial infarction (AMI) treatment by synthesizing evidence from published randomized controlled trials (RCTs).

METHODS:

PubMed, Web of Science, Embase, and Cochrane databases were thoroughly retrieved from inception to November 30, 2024, to identify eligible RCTs comparing empagliflozin with placebo in AMI treatment. The Cochrane Risk of Bias tool was leveraged to detect potential bias. The robustness of the results was examined via sensitivity analyses. Publication bias was evaluated via funnel plots and Egger's test.

RESULTS:

Data from 9 RCTs involving 7,237 AMI patients were analyzed. Meta-analysis revealed that empagliflozin significantly reduced the total hospitalization rate for heart failure (HF) in AMI patients in comparison to placebo (relative risk [RR] = 0.70, 95% confidence interval [CI] = 0.57-0.85). Additionally, empagliflozin significantly improved their ejection fraction (EF) (standard mean difference [SMD] = 1.01, 95% CI = 0.63-1.38), left ventricular global longitudinal strain (LVGLS) (SMD = -0.27, 95% CI = -0.48 to -0.06), body weight (SMD = -0.80, 95% CI = -1.15 to -0.45), and systolic blood pressure (SBP) (SMD = -0.54, 95% CI = -0.88 to -0.20). Statistically significant differences were not noted in other parameters (all p > 0.05). The incidence of adverse events (AEs), such as hepatic dysfunction, contrast-induced nephropathy, and urinary tract infections, did not differ significantly across groups (all p > 0.05). The GRADE rating indicated the evidence for HF hospitalization rate and body weight was of high certainty.

CONCLUSION:

Empagliflozin lowers the total hospitalization rate for HF in AMI patients and significantly improves EF, LVGLS, body weight, and SBP without raising the likelihood of AEs.

897

项与恩格列净相关的新闻（医药）

2025-09-04

·PRNewswire

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期临床1期

2025-09-01

·国家药品监督管理局

2025年09月01日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CXHS2400102泽美妥司他片江苏恒瑞医药股份有限公司国药准字H202500572025年08月26日2CXZS2400023苓桂术甘汤颗粒浙江康恩贝制药股份有限公司国药准字C202500102025年08月26日3CYHB2201126国维生素C注射液武汉久安药业有限公司————2025年08月28日4CYHB2350965注射用头孢他啶广州白云山天心制药股份有限公司————2025年08月29日5CYHB2350966注射用头孢他啶广州白云山天心制药股份有限公司————2025年08月29日6CYHB2450424氨茶碱注射液山西太原药业有限公司国药准字H202581742025年08月29日7CYHB2450439二羟丙茶碱注射液上海信谊金朱药业有限公司国药准字H202581732025年08月29日8CYHB2450536格列喹酮片杭州国光药业股份有限公司————2025年08月29日9CYHB2450608盐酸甲氧氯普胺注射液遂成药业股份有限公司国药准字H202581722025年08月29日10CYHB2501579复方氯化钠注射液沈药合泽药业（山东）有限公司————2025年08月27日11CYHS2202167国钆布醇注射液山东新时代药业有限公司国药准字H202552322025年08月26日12CYHS2202168国钆布醇注射液山东新时代药业有限公司国药准字H202552332025年08月26日13CYHS2202169国钆布醇注射液山东新时代药业有限公司国药准字H202552342025年08月26日14CYHS2301882沙美特罗替卡松吸入粉雾剂上海欧米尼医药科技有限公司国药准字H202552352025年08月26日15CYHS2301945二十碳五烯酸乙酯软胶囊浙江诚意药业股份有限公司国药准字H202552362025年08月26日16CYHS2301946二十碳五烯酸乙酯软胶囊浙江诚意药业股份有限公司国药准字H202552372025年08月26日17CYHS2302200铝碳酸镁混悬液广西百会医药科技有限公司国药准字H202552062025年08月26日18CYHS2302254蒙脱石混悬液南京海纳制药有限公司国药准字H202552122025年08月26日19CYHS2302550利丙双卡因乳膏上海朝晖药业有限公司国药准字H202552072025年08月26日20CYHS2302594盐酸去氧肾上腺素注射液北京海一药业有限公司国药准字H202551872025年08月26日21CYHS2302747吸入用复方异丙托溴铵溶液海南葫芦娃药业集团股份有限公司国药准字H202552132025年08月26日22CYHS2302844盐酸托莫西汀口服溶液广东南国药业有限公司国药准字H202551822025年08月26日23CYHS2302883恩格列净二甲双胍缓释片（Ⅳ）成都地奥制药集团有限公司国药准字H202552052025年08月26日24CYHS2302981二甲双胍恩格列净片（Ⅰ）海南葫芦娃药业集团股份有限公司国药准字H202551882025年08月26日25CYHS2303184、CYHB2400222复方聚乙二醇（3350）电解质散广东赛康制药厂有限公司国药准字H202552382025年08月26日26CYHS2303257注射用硫酸多黏菌素B江苏利泰尔药业有限公司国药准字H202552082025年08月26日27CYHS2303291吗啉硝唑氯化钠注射液重庆圣华曦药业股份有限公司国药准字H202551892025年08月26日28CYHS2303431、CYHB2402055吗啉硝唑氯化钠注射液浙江高跖医药科技股份有限公司国药准字H202551902025年08月26日29CYHS2303435重酒石酸去甲肾上腺素注射液宜昌人福药业有限责任公司国药准字H202551912025年08月26日30CYHS2303523盐酸肾上腺素注射液扬州中宝药业股份有限公司国药准字H202552392025年08月26日31CYHS2303599氨氯地平阿托伐他汀钙片安徽宏业药业有限公司国药准字H202552402025年08月26日32CYHS2303600氨氯地平阿托伐他汀钙片安徽宏业药业有限公司国药准字H202552412025年08月26日33CYHS2303624盐酸肾上腺素注射液华夏生生药业（北京）有限公司国药准字H202552422025年08月26日34CYHS2303641注射用尼可地尔国药集团容生制药有限公司国药准字H202551922025年08月26日35CYHS2400006沙格列汀片安若维他药业泰州有限公司国药准字H202552142025年08月26日36CYHS2400126枸橼酸莫沙必利片宁波美诺华天康药业有限公司国药准字H202551932025年08月26日37CYHS2400133氢溴酸伏硫西汀片普济生物科技（台州）有限公司国药准字H202551942025年08月26日38CYHS2400134氢溴酸伏硫西汀片普济生物科技（台州）有限公司国药准字H202551952025年08月26日39CYHS2400160左氧氟沙星注射液安徽金太阳生化药业有限公司国药准字H202552432025年08月26日40CYHS2400219呋塞米口服溶液健民药业集团股份有限公司国药准字H202551962025年08月26日41CYHS2400238富马酸喹硫平缓释片安徽四环科宝制药有限公司国药准字H202552442025年08月26日42CYHS2400304乌拉地尔缓释胶囊石家庄四药有限公司国药准字H202551972025年08月26日43CYHS2400316法莫替丁注射液辽宁海神联盛制药有限公司国药准字H202552452025年08月26日44CYHS2400374盐酸伊伐布雷定片浙江赛默制药有限公司国药准字H202552152025年08月26日45CYHS2400375盐酸伊伐布雷定片浙江赛默制药有限公司国药准字H202552162025年08月26日46CYHS2400474他达拉非片杨凌吉泰药业有限公司国药准字H202552272025年08月26日47CYHS2400477阿达帕林凝胶杭州领业医药科技有限公司国药准字H202552172025年08月26日48CYHS2400495别嘌醇片石家庄四药有限公司国药准字H202552092025年08月26日49CYHS2400543吗啉硝唑氯化钠注射液华夏生生药业（北京）有限公司国药准字H202551982025年08月26日50CYHS2400555注射用硫酸多黏菌素B四川上善六经医药科技有限公司国药准字H202552102025年08月26日51CYHS2400592、CYHB2402046盐酸非索非那定口服混悬液葵花药业集团重庆小葵花儿童制药有限公司国药准字H202551832025年08月26日52CYHS2400597枸橼酸氢钾钠颗粒浙江赛默制药有限公司国药准字H202552462025年08月26日53CYHS2400620盐酸美金刚口服溶液河北合渡药业有限公司国药准字H202551992025年08月26日54CYHS2400630盐酸屈他维林注射液石家庄四药有限公司国药准字H202552182025年08月26日55CYHS2400811腺苷钴胺胶囊华益药业科技（安徽）有限公司国药准字H202551842025年08月26日56CYHS2400846二十碳五烯酸乙酯软胶囊人福普克药业（武汉）有限公司国药准字H202552472025年08月26日57CYHS2400847二十碳五烯酸乙酯软胶囊人福普克药业（武汉）有限公司国药准字H202552482025年08月26日58CYHS2400848枸橼酸氢钾钠颗粒浙江沣华医药科技有限公司国药准字H202552492025年08月26日59CYHS2400884氨氯地平贝那普利胶囊北京福元医药股份有限公司国药准字H202552002025年08月26日60CYHS2400895盐酸尼卡地平氯化钠注射液石家庄四药有限公司国药准字H202552012025年08月26日61CYHS2400938甲硫酸新斯的明注射液湖南埃威格林医药科技有限公司国药准字H202552502025年08月26日62CYHS2400939甲硫酸新斯的明注射液湖南埃威格林医药科技有限公司国药准字H202552512025年08月26日63CYHS2400954硝苯地平缓释片（II)河北山姆士药业有限公司国药准字H202552022025年08月26日64CYHS2400994西甲硅油乳剂浙江远力健药业有限责任公司国药准字H202552192025年08月26日65CYHS2401006、CYHB2500970甲钴胺片焦作市博信制药有限公司国药准字H202552522025年08月26日66CYHS2401046米拉贝隆缓释片山东朗诺制药有限公司国药准字H202552532025年08月26日67CYHS2401082利丙双卡因乳膏湖北成田药业有限公司国药准字H202552112025年08月26日68CYHS2401098硫酸吗啡缓释片威海路坦制药有限公司国药准字H202552202025年08月26日69CYHS2401214阿卡波糖片山东普瑞曼药业有限公司国药准字H202552542025年08月26日70CYHS2401281玻璃酸钠滴眼液武汉五景药业有限公司国药准字H202552212025年08月26日71CYHS2401296腺苷钴胺胶囊桂林华信制药有限公司国药准字H202551852025年08月26日72CYHS2401298硫酸镁注射液山东齐都药业有限公司国药准字H202551862025年08月26日73CYHS2401299地夸磷索钠滴眼液福建博悦医药科技有限公司国药准字H202552222025年08月26日74CYHS2401321富马酸依美斯汀滴眼液浙江视方极医药科技有限公司国药准字H202552032025年08月26日75CYHS2401397硫酸特布他林雾化吸入用溶液浙江莎普爱思药业股份有限公司国药准字H202552282025年08月26日76CYHS2401472己酮可可碱缓释片山东京卫制药有限公司国药准字H202552552025年08月26日77CYHS2401508复方托吡卡胺滴眼液苏州欧康维视生物科技有限公司国药准字H202552232025年08月26日78CYHS2401587尼莫地平片哈尔滨三联药业股份有限公司国药准字H202552292025年08月26日79CYHS2401683硫酸氢氯吡格雷片重庆药友制药有限责任公司国药准字H202552042025年08月26日80CYHS2401691注射用硫酸艾沙康唑广州一品红制药有限公司国药准字H202552242025年08月26日81CYHS2401692马来酸氯苯那敏注射液江苏瑜兴医药科技有限公司国药准字H202552562025年08月26日82CYHS2401720恩格列净片佑华医药科技有限公司国药准字H202552572025年08月26日83CYHS2401721恩格列净片佑华医药科技有限公司国药准字H202552582025年08月26日84CYHS2401758米格列奈钙片浙江易泽达医药科技有限公司国药准字H202552592025年08月26日85CYHS2401759米格列奈钙片浙江易泽达医药科技有限公司国药准字H202552602025年08月26日86CYHS2401760苯磺酸氨氯地平片新乡市常乐制药有限责任公司国药准字H202552612025年08月26日87CYHS2401762苯磺酸氨氯地平片新乡市常乐制药有限责任公司国药准字H202552622025年08月26日88CYHS2401764盐酸纳呋拉啡口崩片成都苑东生物制药股份有限公司国药准字H202552252025年08月26日89CYHS2401767溴莫尼定噻吗洛尔滴眼液立生医药（苏州）有限公司国药准字H202552632025年08月26日90CYHS2401786注射用盐酸万古霉素华北制药股份有限公司国药准字H202552302025年08月26日91CYHS2401999硝苯地平控释片复星医药（徐州）有限公司国药准字H202552312025年08月26日92CYHS2402124硫酸氨基葡萄糖胶囊通化万通药业股份有限公司国药准字H202552262025年08月26日93CYSB2400015人干扰素α2b凝胶兆科药业（合肥）有限公司————2025年08月27日94CYZB2500269清热卡森颗粒新疆维吾尔药业有限责任公司————2025年08月29日95CYZB2500998复方天麻益阴酒湖南泰阳药业有限公司————2025年08月29日96CYZB2501035清感九味丸内蒙古奥特奇蒙药股份有限公司金山蒙药厂————2025年08月29日97CYZB2501090参芪消渴颗粒陕西诚信制药有限公司————2025年08月29日98CYZB2501103二陈丸贵州德昌祥医药股份有限公司————2025年08月29日99CYZB2501176银杏洋参胶囊广西两面针亿康药业股份有限公司————2025年08月29日100CYZB2501177银杏洋参颗粒广西两面针亿康药业股份有限公司————2025年08月29日101CYZB2501181丹参舒心胶囊上海雷允上药业有限公司————2025年08月29日102CYZB2501185三黄清解片陕西安远堂药业有限公司————2025年08月29日103CYZB2501190三两半药酒温州海鹤药业有限公司————2025年08月29日104CYZB2501192九味痔疮胶囊贵州万胜药业有限责任公司————2025年08月29日105CYZB2501231复方罗汉果止咳颗粒广西维威制药有限公司————2025年08月29日106CYZB2501239蛇伤解毒片福州屏山制药有限公司————2025年08月29日107CYZB2501243伤科七味片上海和黄药业有限公司————2025年08月29日108CYZB2501248冬白梅片通化吉通药业有限公司————2025年08月29日109CYZB2501259通脉颗粒哈尔滨一洲制药有限公司————2025年08月29日110CYZB2501261川郁风寒熨剂大同市利群药业有限责任公司————2025年08月29日111CYZB2501302化积口服液恩威（江西）制药有限公司————2025年08月29日112CYZB2501306三果汤口服液四川巴中普瑞制药有限公司————2025年08月29日113CYZB2501707健儿消食口服液重庆华森制药股份有限公司————2025年08月27日114CYZB2501709感冒退热颗粒湖南湘雅制药有限公司————2025年08月27日115CYZB2501710小儿咳喘灵颗粒湖南湘雅制药有限公司————2025年08月27日116JXHS2400063利司扑兰片罗氏（中国）投资有限公司国药准字HJ202501032025年08月26日117JXHS2500002宗艾替尼片勃林格殷格翰(中国)投资有限公司国药准字HJ202501042025年08月26日118JXSS2500021伊奈利珠单抗注射液常州恒邦药业有限公司国药准字SJ202200072025年08月26日119JYHS2300079盐酸替扎尼定片康龙化成（南京）临床医学研究有限公司国药准字HJ202501002025年08月26日120JYHS2300080盐酸替扎尼定片康龙化成（南京）临床医学研究有限公司国药准字HJ202501012025年08月26日121JYHS2300081盐酸替扎尼定片康龙化成（南京）临床医学研究有限公司国药准字HJ202501022025年08月26日122JYZB2500012樟冰油北京佳禾乐康科技有限公司————2025年08月29日123JYZZ2500005舒筋健络油海南爱欣药业有限公司————2025年08月29日

申请上市临床申请

2025-09-01

·米内网

这家中药龙头厉害了！50个独家中成药亮眼，48款1类新药来势汹汹，11款新药上市可期

精彩内容近日，中药龙头企业康缘药业公布2025年上半年业绩，报告期内实现营业收入16.42亿元，归母净利润1.42亿元，经营性现金流量净额1.44亿元。截至报告期末，公司拥有药品生产批件214个，其中50个为中药独家品种。康缘药业坚持创新驱动，目前公司有33款中药新药在研，其中11款处于NDA/Pre-NDA/III期临床，上市可期；化药及生物药方面，19款1类新药在路上，8个仿制药瞄准40亿市场。手握50个独家中成药！新品研发进展不断康缘药业是一家大型中药企业，目前拥有药品生产批件214个（147个中药、61个化药以及6个原料药），其中50个药品为中药独家品种。公司产品线主要聚焦呼吸与感染、心脑血管、妇科、骨伤科等中医药优势领域，覆盖口服液、注射液、胶囊剂、片剂/丸剂、颗粒剂/冲剂、贴剂、凝胶剂等剂型。 8月28日，康缘药业公布2025年上半年业绩，报告期内实现营业收入16.42亿元，归母净利润1.42亿元，经营性现金流量净额1.44亿元。康缘药业表示，鉴于复杂的外部环境和医药行业政策，以及呼吸、心脑疾病领域药品终端市场需求出现波动等影响，公司面临阶段性业绩承压，销售业绩出现下滑，但公司持续强化内部治理，深化营销学术引领及合规建设。从分产品收入看，2025年上半年康缘药业的注射液、口服液、颗粒剂/冲剂等多个板块产品收入出现下滑，片丸剂、凝胶剂表现亮眼，营业收入同比均有双位数增长。 2025H1康缘药业分产品收入情况（单位：亿元）来源：公司公告，米内网整理虽然康缘药业面临阶段性业绩承压，但公司始终坚持创新驱动，以中医药发展为主体，并积极布局化学药、生物药等新品开发。今年以来，康缘药业持续推动中药新药、化药新药、生物药新药及化药仿制药的研发。中药新药方面，1.1类新药参蒲颗粒、3.1类新药玉女煎颗粒获批上市，分别为盆腔炎后遗症、胃热阴虚证患者提供新的用药选择；1.1类新药六味地黄苷糖片、3.1类新药泻白颗粒及一贯煎颗粒提交NDA，分别用于更年期综合征（肾阴虚证）、小儿肺热咳喘证、肝阴不足/血燥气郁症；1.1类新药麻杏止哮颗粒启动III期临床，适应症为支气管哮喘；固本消疹颗粒（慢性荨麻疹）、连参更年颗粒（更年期综合征）、健脾疏肝固本颗粒（腹泻型肠易激综合征）3款1.1类新药获批临床等。化药1类创新药方面，氟诺哌齐片（阿尔茨海默病）完成II期临床数据统计；Wnt抑制剂KY0135片、EGFR/HER2双重抑制剂KY1702胶囊启动I期临床，均为抗肿瘤药；CCR8特异性抑制剂KYS2301凝胶提交IND并获批临床，用于治疗特应性皮炎等。生物药1类新药方面，NGFR激动剂重组人神经生长因子滴眼液、GLP-1R/GIPR双靶点激动剂ZX2010注射液、GLP-1R/GIPR/GCGR三靶点激动剂ZX2021注射液启动II期临床等。仿制药方面，获得2个药品注册证书，分别为西格列汀二甲双胍片(Ⅱ)、舒马普坦萘普生钠片，其中舒马普坦萘普生钠片为国内首家获批；1个品种顺利通过一致性评价，为替米沙坦胶囊。此外，依折麦布阿托伐他汀钙片(Ⅰ)、布瑞哌唑片、利格列汀片3个品种以新注册分类报产。 29款中药1类新药霸屏，11款中药新药上市可期作为国内中药创新龙头企业，康缘药业自2020年以来保持每年皆有中药新药获批上市的态势，其中2020年拿下筋骨止痛凝胶，2021年拿下银翘清热片，2022年拿下散寒化湿颗粒及苓桂术甘颗粒，2023年拿下济川煎颗粒，2024年拿下温阳解毒颗粒，2025年至今拿下玉女煎颗粒及参蒲颗粒。此外，自2021年以来，康缘药业每年皆有1款及以上的中药1类新药获批临床，2021年有静脉炎颗粒、九味疏风平喘颗粒，2022年有枣柏安神颗粒，2023年有栀黄贴膏、乌鳖还闺颗粒、小儿佛芍和中颗粒、小儿健脾颗粒、五味益心颗粒，2024年有羌芩颗粒、七味脂肝颗粒，2025年至今有固本消疹颗粒、连参更年颗粒、健脾疏肝固本颗粒等。由此可见，康缘药业在中药新药研发方面已形成“上市一批、临床一批、开发一批”的良性循环，并且以未被满足的临床需求为导向，拓宽中药1.1类新药的深度和广度，进一步夯实公司行业龙头地位。米内网数据显示，2024年中国三大终端六大市场（统计范围见文末）中成药合计销售额接近4200亿元。在中成药TOP20一级集团中，康缘药业近年来均上榜。除去已获批上市品种，目前康缘药业有33款中药新药在国内处于申请临床及以上阶段，涵盖呼吸系统、妇科、儿科、消化代谢、心脑血管等中医优势领域。若以中药新注册管理办法计，则中药1类创新药有29个，中药2类改良型新药有2个，古代经典名方中药复方制剂有2个。康缘药业国内在研的中药新药来源：公司公告、米内网综合数据库 1.1类新药龙七胶囊、六味地黄苷糖片，以及3.1类新药泻白颗粒、一贯煎颗粒分别于2024年4月、2025年3月、2025年2月、2025年8月提交NDA，有望于今年或明年迎来好消息，其中龙七胶囊具有祛痰化瘀、清肺消积等功效，有望成为国内获批的首个治疗肺癌的中药创新药。 7款中药新药处于Pre-NDA或III期临床。其中，双鱼颗粒（流感）、紫辛鼻鼽颗粒（鼻炎）、热毒宁颗粒（流感）、麻杏止哮颗粒（支气管哮喘）均为呼吸系统用药。米内网数据显示，2024年中国三大终端六大市场呼吸系统中成药销售额超过840亿元。 12款中药1类新药处于II期临床。其中，七味癸宝颗粒（卵巢功能不全）、正宫胶囊（子宫内膜异位症）、乌鳖还闺颗粒（卵巢功能不全）为妇科用药，芪白平肺颗粒（慢阻肺）、羌芩颗粒（流感）为呼吸系统药物，银杏内酯滴丸（缺血性卒中）、五味益心颗粒（冠心病稳定型心绞痛）为心脑血管疾病药物，小儿佛芍和中颗粒（腹痛）、小儿健脾颗粒（消化不良）为儿科用药等。除了纵向开发中药新药外，康缘药业也在横向培育已上市中药品种，一方面有序推进循证证据研究，另一方面则拓展新适应症。其中，大株红景天胶囊（预防急性高原反应）处于III期临床，金振口服液（儿童病毒性肺炎）、苁蓉总苷胶囊（阿尔茨海默病）、杏贝止咳颗粒（感染后咳嗽）等处于II期临床。 19款化药/生物药1类新药来袭，猛攻2300亿市场在开展创新中药研发与上市品种持续培育的同时，康缘药业在化学药、生物药领域也有所布局，且在2023年后步入高速发展阶段。自2023年以来，康缘药业有9款1类新药（不含引进的新药）在国内首次获批临床，其中2023年有KYS202002A注射液、KY0135片、KY1702胶囊，2024年有注射用AAPB、KYS202004A注射液、KYHY2302乳膏、KYHY2303片、KYS202003A注射液，2025年至今有KYS2301凝胶等。含引进的新药在内，目前康缘药业有19款化药/生物药1类新药在国内处于获批临床及以上阶段，聚焦肿瘤、自身免疫、心脑血管、消化代谢、眼科等治疗领域。康缘药业国内在研的化药及生物药新药来源：米内网综合数据库、公司公告 9款1类新药处于II期临床。其中，ZX2021注射液是一款GLP-1R/GIPR/GCGR三靶点激动剂，目前国内暂无同靶点药物获批，在研新药中，康缘药业的ZX2021、联邦制药的UBT251等处于II期临床，处于研发第一梯队。 8款1类新药处于I期临床。其中，KYS202004A注射液是一款双靶点Fc融合蛋白，可同时阻断TNF-α与IL-17A的信号通路，目前国内外尚无用于治疗银屑病双靶点药物获批上市；KY0135片是一款Wnt信号途径抑制剂，目前国内暂无同靶点药物获批，在研新药中，康缘药业处于研发第一梯队。仿制药方面，目前康缘药业有8个品种以新分类报产在审。从市场规模看，8个品种2024年在中国三大终端六大市场的销售额合计接近40亿元，不乏恩格列净片、利格列汀片等超10亿大品种；从市场格局看，有2个品种暂无首仿（含剂型首仿）获批上市，分别为布瑞哌唑片、色甘酸钠吸入溶液。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月29日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

财报临床1期申请上市临床3期临床申请

100 项与恩格列净相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10459	恩格列净	A10BK03	DB09038

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心血管疾病	中国	Boehringer Ingelheim International GmbH	2023-05-26
心血管疾病	中国	Boehringer Ingelheim GmbH	2023-05-26
射血分数保留型心力衰竭	中国	Boehringer Ingelheim International GmbH	2022-08-30
射血分数保留型心力衰竭	中国	勃林格殷格翰（中国）投资有限公司	2022-08-30
射血分数降低的心力衰竭	中国	Boehringer Ingelheim GmbH	2022-06-10
射血分数降低的心力衰竭	中国	Boehringer Ingelheim International GmbH	2022-06-10
慢性心力衰竭	欧盟	Boehringer Ingelheim International GmbH	2014-05-22
慢性心力衰竭	冰岛	Boehringer Ingelheim International GmbH	2014-05-22
慢性心力衰竭	列支敦士登	Boehringer Ingelheim International GmbH	2014-05-22
慢性心力衰竭	挪威	Boehringer Ingelheim International GmbH	2014-05-22
慢性肾病	澳大利亚	Boehringer Ingelheim Pty Ltd.	2014-04-30
2型糖尿病	澳大利亚	Boehringer Ingelheim Pty Ltd.	2014-04-30
心脏衰竭	澳大利亚	Boehringer Ingelheim Pty Ltd.	2014-04-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性心脏缺损	临床3期	加拿大	Boehringer Ingelheim GmbH	2025-05-01
肾性糖尿	临床3期	-	Tanta University	2023-01-01
精神分裂症	临床3期	-	Tanta University	2023-01-01
非酒精性脂肪性肝炎	临床3期	埃及	Tanta University	2022-11-01
低血糖	临床3期	瑞士	Boehringer Ingelheim GmbH	2022-03-11
急性心肌梗塞	临床3期	美国	Boehringer Ingelheim Pharma GmbH & Co., KG	2020-12-16
急性心肌梗塞	临床3期	美国	Boehringer Ingelheim International GmbH	2020-12-16
急性心肌梗塞	临床3期	美国	Eli Lilly & Co.	2020-12-16
急性心肌梗塞	临床3期	美国	Boehringer Ingelheim GmbH	2020-12-16
急性心肌梗塞	临床3期	中国	Boehringer Ingelheim GmbH	2020-12-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03594110 (EMPA-KIDNEY, Pubmed \| EClinicalMedicine)	临床3期	慢性肾病	6,609	Empagliflozin 10 mg	襯壓齋範蓋獵獵夢鬱築(襯製顧簾選窪觸鹹網遞) = 窪鹹願觸遞糧製夢蓋構衊鹽簾衊夢壓遞構願襯 (夢鏇齋鏇製蓋觸憲齋糧 )	积极	2025-07-01
NCT05262764 (Pubmed \| Expert Opin Drug Saf)	N/A	心脏衰竭 type 2 diabetes	-	Empagliflozin	淵製鹹齋齋範廠餘餘夢(獵積鏇淵鬱壓夢積壓構) = 衊築鬱觸簾淵願襯選蓋選夢範壓選膚膚鬱膚鑰 (製艱艱觸廠鹽鏇獵窪簾 ) 更多	积极	2025-06-18
NCT03753087 (Pubmed \| Cardiovasc Diabetol)	临床4期	2型糖尿病 \| 射血分数保留型心力衰竭 N-terminal pro-brain natriuretic peptide (NT-proBNP) \| sST2	70	Empagliflozin 10 mg	遞壓選構願艱糧糧衊窪(蓋膚憲選襯糧憲鬱窪構) = 積餘鹹壓願願繭顧鑰鬱鑰鑰餘積鏇窪鹹顧繭齋 (構鏇齋襯構衊鹽艱壓衊 )	积极	2025-05-09
				empagliflozin (Control Group)	遞壓選構願艱糧糧衊窪(蓋膚憲選襯糧憲鬱窪構) = 構觸夢艱選遞鑰襯鏇襯鑰鑰餘積鏇窪鹹顧繭齋 (構鏇齋襯構衊鹽艱壓衊 )
NCT05282121 (CTgov)	临床2期	甲型肝炎 \| 食管胃静脉曲张 \| 非酒精性脂肪性肝炎 ... 更多	90	Avenciguat (Patients With HBV - Avenciguat)	鏇簾蓋鑰糧遞蓋構遞淵(願鹽廠鹹獵積鏇艱膚顧) = 夢餘淵鏇積醖夢壓夢襯餘蓋選築淵夢糧夢鹽壓 (齋鏇觸窪簾鹽鏇憲廠蓋, 6.66) 更多	-	2025-04-29
				Avenciguat (Patients With HCV - Avenciguat)	鏇簾蓋鑰糧遞蓋構遞淵(願鹽廠鹹獵積鏇艱膚顧) = 積膚衊醖構壓遞窪積蓋餘蓋選築淵夢糧夢鹽壓 (齋鏇觸窪簾鹽鏇憲廠蓋, 7.09) 更多
NCT03485092 (SUGAR-DM-HF, Pubmed \| Eur J Heart Fail)	临床4期	射血分数降低的心力衰竭	105	Empagliflozin 10 mg	簾糧醖壓醖簾膚繭憲積(觸遞淵淵壓廠鬱窪醖簾) = 構鏇蓋蓋醖觸鑰製網鏇夢鑰窪廠網醖範餘衊憲 (網憲築蓋憲廠艱壓壓醖, 2.5)	积极	2025-01-10
				Placebo	-
NCT04509674 (EMPACT-MI, CTgov)	临床3期	心脏衰竭 \| 急性心肌梗塞	6,522	Placebo (Placebo)	製簾繭鏇顧壓選淵窪選 = 壓顧醖獵願夢餘簾獵遞壓襯淵淵範醖製獵蓋衊 (鹽淵壓顧範築遞蓋糧繭, 淵膚鏇淵廠餘積網網範 ~ 獵廠醖鏇夢壓糧範繭願) 更多	-	2025-01-07
				Empagliflozin (Empagliflozin 10 mg)	製簾繭鏇顧壓選淵窪選 = 壓簾膚襯鏇選鹽廠製構壓襯淵淵範醖製獵蓋衊 (鹽淵壓顧範築遞蓋糧繭, 簾膚壓製鹽壓糧獵構齋 ~ 醖憲壓餘觸選顧築築窪) 更多
NCT03594110 (EMPA-KIDNEY, Pubmed \| N Engl J Med)	临床3期	慢性肾病 estimated glomerular filtration rate (eGFR) \| urinary albumin-to-creatinine ratio	6,609	Empagliflozin 10 mg	鑰餘選鹹壓衊壓觸淵壓(蓋蓋衊夢窪鹹糧繭觸鹽) = 鹹夢築遞蓋選艱願鏇壓夢憲顧艱糧積膚選築願 (網廠鬱鏇積築餘鹽衊襯 ) 更多	积极	2024-10-25
				Placebo	鑰餘選鹹壓衊壓觸淵壓(蓋蓋衊夢窪鹹糧繭觸鹽) = 艱膚積憲鬱襯構窪簾選夢憲顧艱糧積膚選築願 (網廠鬱鏇積築餘鹽衊襯 ) 更多
NCT03087773 (EMMY, Pubmed \| Clin Res Cardiol)	临床3期	心肌梗塞	313	Empagliflozin	簾鏇積餘鹹願鑰醖衊願(鹹鏇齋鏇憲網鏇獵選選) = parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort 選鬱憲艱網觸艱顧遞鏇 (餘鏇顧願積繭製廠網繭 ) 更多	积极	2024-09-16
				Placebo
NCT04509674 (EMPACT-MI, NEWS) 人工标引	临床3期	急性心肌梗塞	-	Empagliflozin	餘獵積積夢夢衊構觸構(醖範淵鑰齋餘願簾鏇簾) = 餘遞壓憲鏇膚遞獵壓網網餘蓋廠醖鬱艱繭襯繭 (繭窪觸遞襯鏇顧齋繭獵 )	积极	2024-09-09
				Placebo	餘獵積積夢夢衊構觸構(醖範淵鑰齋餘願簾鏇簾) = 壓鑰膚築餘鹽鑰鑰築繭網餘蓋廠醖鬱艱繭襯繭 (繭窪觸遞襯鏇顧齋繭獵 )
ESC2024	N/A	慢性阻塞性肺疾病 \| 心脏衰竭	-	Empagliflozin	繭夢淵夢襯獵艱艱願餘(簾襯築淵範鹹顧廠觸鬱) = 遞齋遞蓋憲鬱壓繭網遞淵餘製夢選築鹽鏇獵鏇 (蓋簾願構獵糧憲糧獵膚 ) 更多	-	2024-08-31
				Placebo	繭夢淵夢襯獵艱艱願餘(簾襯築淵範鹹顧廠觸鬱) = 獵衊壓淵簾糧鏇廠鑰壓淵餘製夢選築鹽鏇獵鏇 (蓋簾願構獵糧憲糧獵膚 ) 更多